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Abstract
Background: Periconceptional use of vitamin supplements containing folic acid reduces the risk of a neural tube defect (NTD).
In November 1998, food fortification with folic acid was mandated in Canada, as a public health strategy to increase the folic
acid intake of all women of childbearing age. We undertook a comprehensive population based study in Newfoundland to assess
the benefits and possible adverse effects of this intervention.
Methods: This study was carried out in women aged 19–44 years and in seniors from November 1997 to March 1998, and
from November 2000 to March 2001. The evaluation was comprised of four components: I) Determination of rates of NTDs;
II) Dietary assessment; III) Blood analysis; IV) Assessment of knowledge and use of folic acid supplements.
Results: The annual rates of NTDs in Newfoundland varied greatly between 1976 and 1997, with a mean rate of 3.40 per 1,000
births. There was no significant change in the average rates between 1991–93 and 1994–97 (relative risk [RR] 1.01, 95%
confidence interval [CI] 0.76–1.34). The rates of NTDs fell by 78% (95% CI 65%–86%) after the implementation of folic acid
fortification, from an average of 4.36 per 1,000 births during 1991–1997 to 0.96 per 1,000 births during 1998–2001 (RR 0.22,
95% CI 0.14–0.35). The average dietary intake of folic acid due to fortification was 70 µg/day in women aged 19–44 years and
74 µg/day in seniors. There were significant increases in serum and RBC folate levels for women and seniors after mandatory
fortification. Among seniors, there were no significant changes in indices typical of vitamin B12 deficiencies, and no evidence of
improved folate status masking haematological manifestations of vitamin B12 deficiency. The proportion of women aged 19–44
years taking a vitamin supplement containing folic acid increased from 17% to 28%.
Conclusions: Based on these findings, mandatory food fortification in Canada should continue at the current levels. Public
education regarding folic acid supplement use by women of childbearing age should also continue.
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Background
Neural tube defects (NTDs) are birth defects resulting
from the failure of neural tube closure during early devel-
opment of the human embryo. The 1997 Canadian
national NTD birth prevalence was 0.75 per 1,000 births
(live births and stillbirths), down from 1.16 per 1,000 in
1989 [1]. The rates tend to be higher in the eastern prov-
inces than in the west [2-4]. Historically, Newfoundland
has had one of the highest rates in North America with a
reported average yearly rate for 1976–1997 of 3.4 per
1,000 births (including live births, stillbirths and fetuses
from pregnancies terminated after a prenatal diagnosis of
an NTD) [4].
Evidence from a number of studies has demonstrated that
periconceptional use of vitamin supplements containing
folic acid reduces the risk of NTDs [5-8]. Although the
mechanism of action of this nutrient in influencing the
risk of NTDs is poorly understood, the evidence of the
benefit of folic acid has led many health organizations
since late 1992 to recommend periconceptional folic acid
supplementation, at a level of 400 µg /day for low risk
women [9-11].
Because of concern that public education campaigns
alone would not be effective in achieving optimal peri-
conceptional folic acid intake for the majority of women,
food fortification with folic acid was proposed as a strat-
egy to ensure that all women of childbearing age increase
their dietary intake of this vitamin. In November 1998,
Health Canada mandated fortification of white flour and
enriched pasta and cornmeal with folic acid [12]. Since
diets vary, it was known that it would be virtually impos-
sible to fortify food with folic acid at a level that ensures
that the target population receives an additional 400 µg /
day, while protecting the non-targeted population from
an undesirably high amount. As a result, conservative lev-
els of fortification were introduced. White flour is fortified
with folic acid at a level of 0.15 mg per 100 g of flour. This
intervention was expected to increase the average daily
folic acid intake of women of childbearing age by about
100 µg [13].
The question of whether folic acid fortification of grain
products poses any serious health risk has been controver-
sial. The main concern has been the potential masking of
vitamin B12 deficiency, a condition that affects 10–15% of
the population over age 60 years [14,15]. Increased folic
acid intake may correct the haematologic signs of vitamin
B12 deficiency, thus delaying diagnosis and treatment of
the condition while its attendant neurologic manifesta-
tions progress. Seniors may be at particular risk since the
incidence of vitamin B12 deficiency increases with age.
We therefore undertook a comprehensive population
based study to evaluate the effectiveness of the public
health strategy of food fortification with folic acid and to
determine possible adverse effects resulting from
fortification.
Methods
Study design
This evaluative study was designed as a population based
study and included four components as follows: I) Deter-
mination of rates of NTDs; II) Dietary assessment; III)
Blood analysis; IV) Assessment of knowledge and use of
folic acid supplements. The latter three components of the
study were carried out in two phases; the first phase took
place prior to the introduction of mandatory fortification,
from November 1997 to March 1998 and the second
phase occurred from November 2000 to March 2001,
after two years of implementation of mandatory
fortification.
This study was undertaken in Newfoundland because of
the historically high rates of NTDs in the province, and
because of strong interest in the health community in this
initiative. Newfoundland and Labrador, with a popula-
tion of approximately 500,000, has about 5,000 births
annually. An urban (St. John's) and rural (Clarenville,
Port Blandford, Random Island area) location in the prov-
ince were chosen as the sites for this study. Data collected
from these sites were compared between Phase I (Novem-
ber 1997 to March 1998) and Phase II (November 2000
to March 2001). Table 1 shows schematically the frame-
work including objectives and sampling of subjects for
this study. As part of this project, dietary assessment,
blood analysis and assessment of knowledge and use of
supplements were also carried out in a 2-phase popula-
tion based study of women of reproductive age in King-
ston, Ontario and environs. The results of this study will
be reported elsewhere.
Data collection
In order to examine temporal changes in the rates of NTDs
in Newfoundland, data were compiled from the New-
foundland and Labrador Medical Genetics Program from
1976 to 2001. This Program ascertains cases of NTDs
annually and maintains an NTD database. The database
has recorded cases of NTD since 1976. Cases are identified
in the following ways: provincial live birth and stillbirth
notification forms, maternal-fetal medicine referrals (only
one tertiary care unit in the province), and letters sent to
all medical records departments of all provincial hospitals
requesting data on cases assigned ICD-9/10 codes associ-
ated with NTDs or terminations for NTDs. These multiple
sources are utilized to ensure complete ascertainment.
NTD cases include anencephaly, spina bifida and enceph-
alocele diagnosed in live births, stillbirths (a gestationalBMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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age of 20 weeks and above or birthweight of 500 g and
above) and fetuses from pregnancies terminated (at any
gestational age) after a prenatal diagnosis of an NTD.
For the knowledge assessment component of the study,
women between the ages of 19 and 44 years were
recruited through a random telephone survey. In the ini-
tial telephone survey, women were asked about their use
of vitamin supplements and knowledge of the importance
of folic acid for reducing the risk of NTDs or for fetal
development. Women who completed the initial tele-
phone survey were subsequently screened for their eligi-
bility for dietary and blood assessments. Women who
were not taking supplements containing folic acid and not
pregnant were eligible to participate. This sampling proce-
dure for Phase I and Phase II resulted in a response rate of
59.7% and 65.4%, respectively, with no difference
between urban and rural response rates. A total of 233
women were recruited into Phase I and 204 women were
recruited in Phase II, who completed components II, III
and IV of the study.
Seniors were recruited in the same manner as the samples
of women, but were drawn only from St. John's, New-
foundland. Seniors aged 65 years or over, not diagnosed
with vitamin B12 deficiency or anaemia and not taking
vitamin B12 or supplements containing folic acid, were eli-
gible for dietary and blood sample assessments. A total of
202 seniors were recruited in Phase I and 186 were
recruited in Phase II (response rate 45.1% and 44.9%,
respectively).
In order to determine intakes of naturally occurring folate
(the form of the vitamin found naturally in foods) pre and
post fortification, and dietary intakes of folic acid (the
synthetic form of the vitamin) post fortification, a Willett
food frequency dietary questionnaire [16] was adminis-
tered to subjects during an in-person interview. There
were some modifications to the questionnaire to include
common Newfoundland foods and to ensure that all
foods high in folate were included. The dietary question-
naire was used to estimate an average frequency of con-
sumption of 124 food items over the previous period of
one year.
The women and senior participants were also asked to
provide a sample of blood in order to determine blood
folate and vitamin B12 status in Phase I and Phase II. Lab-
oratory tests for complete blood count (CBC), red blood
cell (RBC) folate, serum folate, creatinine, vitamin B12,
plasma homocysteine (HCY) and methylmalonic acid
(MMA) were conducted at the laboratories of the Health
Care Corporation of St. John's.
Data analysis
Rate of NTDs was defined as the number of above
described NTD cases, divided by the total number of live
births, stillbirths, and pregnancy terminations for an NTD
(termed as "births" hereafter). First we examined the tem-
poral trend in annual rates of NTDs from 1976 to 2001
using 3-year moving average rates, then we focused on
comparison of the NTD data for the most recent 11 years,
identified as pre-supplementation (1991–1993), pre-for-
tification (1994–1997) and post-fortification (1998–
2001). We regard the year 1997 as a transition period, or
partial fortification period, since fortification of white
flour and enriched pasta and cornmeal was permitted in
Canada as of December 1996 [17]. Thus we also analysed
the NTD data using 1994–1996 as a pre-fortification
period.
Mean daily intakes of naturally occurring folate were cal-
culated for women aged 19–44 years and for seniors in
Phase I and Phase II. Also, for Phase II, average daily
intakes of folic acid from fortified foods were calculated.
Table 1: Framework for a two phase, multi site study to examine the effects of food fortification with folic acid
Content Study objective Sample ** Location
I. Rates of NTDs Determine rate of NTD-affected pregnancies, 
pre and post fortification
Newfoundland population Newfoundland
II. Dietary assessment* Determine dietary intake of folate, pre and post 
Fortification
A) Non-pregnant women of childbearing age 
(19–44 years), not taking supplements 
containing folic acid;
St. John's, Rural 
Newfoundland
III. Blood analysis* Determine blood folate and vitamin B12 status, 
pre and post fortification
B) Seniors (65 years or older) not taking 
supplements containing folic acid or B12 
supplement and not diagnosed with anaemia.
St. John's, Rural 
Newfoundland
IV. Knowledge and intake 
of folic acid supplements
Determine knowledge and consumption of folic 
acid supplements, pre and post fortification
Non-pregnant women of childbearing age (19–
44 years)
St. John's, Rural 
Newfoundland
* The same sample of women and seniors are analyzed in Components II and III.
** Sampling was done separately for Phases I and II.BMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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Data from the blood analyses were tested for normality
with the Komogorov-Smirnov test, and differences
between groups were tested using the non-parametric
Mann-Whitney U test. The distributions of plasma MMA,
plasma HCY, serum folate, RBC folate and serum vitamin
B12were skewed. Values were therefore log transformed to
give an approximate normal distribution for estimation of
geometric mean and confidence intervals. Unless other-
wise stated, all laboratory values presented in this paper
are geometric means and 95% confidence intervals (CI).
Differences in the frequency of high or low results based
on reference values were tested by Pearson chi-square
statistics.
All data for this study were entered into SPSS (the Statisti-
cal Package for Social Sciences) Rel. 10.0 after the end of
each phase. Data from the dietary interviews were ana-
lyzed using Epi-Info (Version 6.04d), while the laboratory
data and the data about knowledge and use of supple-
ments were analyzed using SPSS.
Results
1. Rate of NTDs
There were 617 ascertained cases of NTD among live
births, stillbirths and pregnancies terminated for an NTD
in Newfoundland over the 26 year period. The annual
rates of NTDs in the province varied greatly over time,
with the lowest rate of 2.18 per 1,000 births in 1989, and
the highest rate of 5.92 per 1,000 births in 1995. The aver-
age rate of NTDs between 1976 and 1997 was 3.40 per
1,000 births. A dramatic drop is seen in 1997, in which
the rate of NTDs was 2.20 per 1,000 births, down from
5.49 per 1,000 births in the previous year. The decreasing
trend continued after 1998 (Figure 1 shows 3-year moving
average rates).
The NTD data for the years 1991–2001 are presented in
three periods in Table 2. The mean annual rates were 4.35
per 1,000 births during 1991–1993 and 5.02 per 1,000
births during 1994–1996 (1994–96 vs 1991–93, relative
risk [RR] 1.15, 95% CI 0.86–1.54, p = 0.95), and 4.37 per
1,000 births during 1994–1997 (1994–97 vs 1991–93,
RR 1.01, 95% CI 0.76–1.34, p = 0.54).
The total annual rate of NTDs fell by 78% after the imple-
mentation of folic acid fortification, from an average of
4.36 per 1,000 births during 1991–1997 to 0.96 per 1,000
births during 1998–2001 (RR 0.22, 95% CI 0.14–0.35, p
< 0.0001). It is worthwhile to note that there has been no
significant increase in the proportion of NTDs from termi-
nated pregnancies since 1994.
Rates of NTDs in Newfoundland and Labrador, 1976 to 2001 (3-year moving average rates) Figure 1
Rates of NTDs in Newfoundland and Labrador, 1976 to 2001 (3-year moving average rates) *The rate for 1976 is 
a 2-yr average based on data for 1976 and 1977 and the rate for 2001 is a 2-yr average based on data for 2000 and 2001.BMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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II. Dietary Assessment
There was no statistically significant change in the average
daily intake of naturally occurring folate among either
women aged 19–44 years or seniors between Phase I and
Phase II (p = 0.19 and p = 0.18, respectively). Seniors gen-
erally had dietary folate intake slightly higher than
women of childbearing age. In Phase I, the average daily
intake of naturally occurring folate was 306 µg/day for
seniors and 262 µg/day for women aged 19–44 years,
while in Phase II, the average daily intake of naturally
occurring folate was 290 µg/day for seniors and 248 µg/
day for women aged 19–44 years.
The implementation of mandatory fortification resulted
in an average additional dietary intake of 70 µg/day of
folic acid in women aged 19–44, and 74 µg/day of folic
acid among seniors. It is noteworthy that for the women
the average daily folic acid intake due to food fortification
was less than the approximately 100 µg that was previ-
ously predicted for women of childbearing age. The max-
imum dietary intake of folic acid due to fortification for
an individual woman was 235 µg/day, and for an individ-
ual senior was 219 µg/day.
III. Blood Analysis
Serum folate and RBC folate increased significantly from
Phase I to Phase II in both women aged 19–44 years and
seniors (p < 0.001). For both age groups, there was a cor-
responding decrease in mean plasma HCY levels (Tables 3
and 4). The prevalence of low serum folate (≤6.8 nmol/L)
was eliminated from the sample of seniors and the pro-
portion of elderly participants with low stores as indicated
by RBC folate levels (< 373 nmol/L) was reduced from
2.5% to 1.6%. The proportion of women aged 19–44
years with high HCY(>13.2 µmol/L) also decreased from
15.9% to 7.6% (p = 0.002) (data not shown).
There was a significant increase in mean vitamin B12 levels
in women aged 19–44 and seniors (p = 0.020 and p <
0.001, respectively, Tables 3 and 4). The proportion of
seniors with low vitamin B12 (<133 pmol/L) was 18.8%
prior to fortification and following fortification this pro-
portion declined to 11.8% (p = 0.032) (data not shown).
A statistically significant increase in mean plasma MMA
levels was observed in women subjects (p = 0.008) but not
in seniors (p = 0.229) (Tables 3 and 4). There was also an
increase in the proportion of women aged 19–44 years
with MMA values above the upper reference value of 0.37
µmol/L from 3.6% in Phase I to 14.9% in Phase II (p <
0.001). There was no significant change in the proportion
of abnormal MMA values in seniors. Moreover, among
seniors, blood analysis showed no significant difference
Table 2: Annual rates of neural tube defects (NTDs) in Newfoundland and Labrador before folic acid supplementation (1991–1993), 
prior to folic acid fortification (1994–1997) and after fortification (1998–2001)
Period No. of cases of NTDs Total no. of births* Rate per 1,000 births
In live births and 
stillbirths
In terminated 
pregnancies
Total
Pre-supplementation
1991–1993 50 40 90 20,711 4.35
Pre-fortification
1994–1997 53 50 103 23,592 4.37
Post-fortification
1998–2001 8 11 19 19,816 0.96
* The total number of births includes live births, stillbirths and terminations for an NTD.
Table 3: Laboratory data (geometric mean and 95% confidence interval) for young women participants (age 19–44 years) in Phase I and 
Phase II
Characteristic Phase I Phase II p value †
Total participants (n) 233 204
Serum folate (nmol/L) 13.5 (12.9 – 14.1) 18.1 (17.3 – 18.9) <0.001
RBC folate (mol/L) 625 (601 – 649) 818 (784 – 854) <0.001
Plasma HCY (µmol/L) 10.2 (9.8 – 10.7) 9.2 (8.8 – 9.6) 0.001
Serum vitamin B12 (pmol/L) 177 (169 – 186) 200 (190 – 211) 0.02
Plasma MMA (µmol/L) 0.18 (0.17 – 0.19) 0.21 (0.19 – 0.22) 0.008
† P value for the difference between Phase I and Phase II is based on a non-parametric Mann-Whitney U test.
RBC denotes red blood cell, HCY denotes homocysteine, and MMA refers to methylmalonic acid.BMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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in mean haemoglobin concentrations, mean corpuscular
volume (MCV), or proportion with abnormally high MCV
(>99 fL) or low haemoglobin (<120 g/L) concentrations.
IV. Knowledge and use of folic acid supplements
There was a significant increase from Phase I to Phase II in
the proportion of women aged 19–44 years who knew the
importance of folic acid (from 33% to 46%, p < 0.001).
The proportion of women taking a vitamin supplement
containing folic acid increased substantially between the
two time periods (from 17% to 28%, p < 0.003). Informa-
tion about folic acid dosage was not collected.
Discussion
The results of a number of studies have led to the conclu-
sion that periconceptional folic acid supplementation
reduces the risk of NTDs [5-8]. Among the responses to
this research evidence were calls in the early 1990s for
mandatory fortification of food with folic acid. It was
argued that this public health intervention would address
concerns about achieving population level compliance
with recommendations to women to take vitamin supple-
ments containing folic acid before becoming pregnant
and in the first weeks of pregnancy. These concerns were
borne out in several Canadian studies suggesting that
many caregivers [18,19] and women [20,21] remained
unaware of the relationship between folic acid and NTDs.
More recent studies have shown an increase in knowledge
about folic acid, but supplementation rates remain low
[22-25].
In March 1996 the US Food and Drug Administration
(FDA) announced that it would permit addition of folic
acid to enriched flour and other enriched cereal grain
products, and that this addition would be mandatory as of
January 1998. The level of fortification was set at 0.14 mg
folic acid per 100 g of cereal grain product. It was deter-
mined that at this level of fortification, the intake of folate
(from all sources) for the target and the general
population would be kept below 1,000 µg/day, which was
deemed to be the safe upper limit. This level of
fortification was estimated to increase the average daily
intake of folic acid in women of childbearing age by about
100 µg [26]. Subsequent to the US decision, Canada fol-
lowed suit, permitting folic acid fortification at an equiv-
alent level in December 1996 (addition of folic acid to
white flour and enriched pasta and cornmeal at 0.15 mg
folic acid per 100 g of flour and 0.20 mg folic acid per 100
g of pasta). In Canada, fortification became mandatory in
November 1998.
Rate of NTDs
Our results show a highly significant drop in the rate of
NTDs in Newfoundland, taking into account all identified
affected pregnancies (live births, stillbirths and pregnan-
cies terminated after a prenatal diagnosis of an NTD). The
78% (95% CI 65%–86%) reduction in the NTD rate after
implementation of fortification is greater than the 18%–
22% reduction predicted at current levels of fortification
[27,28], and greater than the 19% reduction in birth prev-
alence of NTDs reported in the US after mandatory fortifi-
cation [29]. The results in Newfoundland are closer to the
54% reduction (95% CI 34%–68%) in rate of NTDs
reported in Nova Scotia after fortification [2]. De Wals et
al. observed a 32% reduction (95% CI 23%–41%) in
NTDs in Quebec between 1992–97 and 1998–2000 [30].
Ray et al. [31] analyzed maternal serum screening data for
Ontario and observed a decline in NTD prevalence from
1.13 per 1,000 pregnancies before fortification to 0.58 per
1,000 pregnancies thereafter (prevalence ratio 0.52, 95%
CI 0.40–0.67).
The large reduction in the rate of NTDs in Newfoundland
may be due, at least in part, to the fact that Newfoundland
had higher background rates of NTDs. This population
may be more sensitive to the influence of folic acid. In a
large-scale public health campaign in northern and south-
ern China, periconceptional use of 400 µg/day folic acid
Table 4: Laboratory data (geometric mean and 95% confidence interval) for senior participants (age 65 years or over) between Phase I 
and Phase II
Characteristic Phase I Phase II P value ‡
Total participants (n) 202 186
Serum folate (nmol/L) 14.8 (14.0 – 15.6) 23.0 (22.0 – 24.1) <0.001
RBC folate (mol/L) 745 (713 – 779) 916 (873 – 961)† <0.001
Plasma HCY (µmol/L) 13.6 (13.0 – 14.2)† 12.3 (11.7 – 12.9)† 0.001
Serum vitamin B12 (pmol/L) 183 (173 – 194) 216 (202 – 231) <0.001
Plasma MMA (µmol/L) 0.24 (0.22 – 0.27)† 0.26 (0.24 – 0.28) 0.229
† The Komogorov-Smirnov test showed that the log transformed data were non-normal (p < 0.05).
‡ P value for the difference between Phase I and Phase II is based on a non-parametric Mann-Whitney U test.
RBC denotes red blood cell, HCY denotes homocysteine and MMA refers to methylmalonic acid.BMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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supplements was associated with a reduction in NTD risk
of 79% for women in northern China, where the baseline
NTD rate was high and similar to that observed in New-
foundland. A lower risk reduction of 41% was observed in
the southern region where the pre-campaign NTD rate
was much lower [32].
The 65% increase in the proportion of women taking vita-
min supplements containing folic acid, from 17% in
Phase I to 28% in Phase II, suggests that an increasing
trend in folic acid supplementation may have played a
role in the declining NTD rate in Newfoundland. In this
study it was not possible to determine the individual con-
tribution of supplementation and fortification to the
trend in NTDs.
The annual rate of NTDs in the pre-fortification period
(1994–97) did not differ significantly from that of the
pre-supplementation period (1991–93); this is true
whether 1997 is excluded or included in the pre-fortifica-
tion period. The increase in the rates of NTDs in 1995 and
1996 appears random and largely unexplainable. The
changes in the NTD rates between 1994–1996 and 1991–
1993 and between 1995–1997 and 1991–1993 were not
statistically significant. In addition, our data do not show
an obvious increase in the proportion of NTDs in termi-
nated pregnancies during 1994 and 1996 (data available
upon request).
Dietary intakes and blood folate levels
The questionnaire used in this dietary assessment was a
modified Willett questionnaire [16], administered in a
face-to-face interview with trained personnel. The Willett
food frequency dietary questionnaire has been well vali-
dated [33] and proved easy to administer for this sample
population.
The daily intake of naturally occurring folate among
women aged 19–44 years in this study (average 248 µg/
day in the Phase II sample) was similar to values found in
other studies of women's diet [34,35]. For seniors in
Phase II, naturally occurring folate in the diet averaged
290 µg/day which was comparable to values found for
persons age 49 and older in an Australian study [36]. The
dietary folic acid intake due to fortification did not exceed
the Tolerable Upper Intake Level (UL) of 1,000 µg folic
acid/day [14] for any of the participants (this UL for folic
acid does not include naturally occurring folate). It is
important to note that this part of the study excluded per-
sons taking vitamin supplements containing folic acid.
While it was not possible to estimate the proportion of
people in the general Newfoundland population who
may be consuming more than 1,000 µg/day of folic acid
from fortification and supplementation combined, it is
likely that this proportion is small. The average dietary
intake and maximum intake of folic acid due to fortifica-
tion were 70 µg/day and 235 µg/day, respectively, for
women aged 19–44 years, and 74 µg/day and 219 µg/day,
respectively, for seniors. The average folic acid dose in
folic acid containing over-the-counter supplements mar-
keted in Canada is about 350 µg/day (Health Canada
unpublished information).
The results of this study provide strong evidence of
improved blood folate status in women aged 19–44 years
following mandatory fortification with folic acid. Women
showed evidence of increased levels of serum and RBC
folate and decreased levels of plasma HCY. These results
are consistent with an earlier study examining the effect of
fortification in the Framingham offspring study cohort
[37].
Mandatory food fortification with folic acid has resulted
in improvements in folate indices in seniors. Both mean
serum folate and mean RBC folate increased following
folic acid fortification (55% and 23%, respectively, Table
4). Consistent with this was a moderate decrease in mean
plasma HCY levels among seniors by 1.3 µmol/L. Fortifi-
cation of food with folic acid and an upward shift in
blood folate levels is of benefit to the elderly population
especially with regard to risk of cardiovascular disease.
High levels of homocysteine are associated with both cer-
ebrovascular and coronary heart disease [38-40].
Vitamin B12 status
There was a decline in the proportion of seniors with low
vitamin B12 levels, and there was actually a slight increase
in mean vitamin B12 levels. In vitamin B12 deficiency,
plasma MMA is usually elevated. Plasma MMA is believed
to be a better indicator of vitamin B12 status at the tissue
level than serum vitamin B12 levels are. Our study showed
no change in mean MMA levels nor increased proportion
of elderly with high levels. In addition, there was no
change in the indicators of anaemia (i.e., haemoglobin
and MCV) in seniors post fortification in our study. Thus,
these results show no evidence of a deterioration in vita-
min B12 status among seniors. Furthermore, there is no
evidence of improved folate status resulting in masking of
the haematological manifestations of vitamin B12 defi-
ciency among seniors as a group. There was no evidence
of deteriorating vitamin B12 status among young women
participants based on vitamin B12 measurements. The
upward trend in plasma MMA levels and higher propor-
tion of abnormal values among young women is being
further evaluated. It is unlikely that this is a direct effect of
folic acid fortification and this observation is not consist-
ent with any known effects of folic acid on vitamin B12 sta-
tus.BMC Pregnancy and Childbirth 2004, 4:20 http://www.biomedcentral.com/1471-2393/4/20
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Limitations
We have documented the rate of NTDs among live births,
stillbirths and terminated pregnancies known to have an
NTD. It was not possible to include NTDs that may have
occurred in pregnancies that resulted in a spontaneous
abortion or a termination that occurred for reasons other
than a congenital anomaly.
This study, and other studies of fortification in Canada,
are limited by the fact that there was no precise date when
exposure to food fortified with folic acid began. The addi-
tion of folic acid to white flour and enriched pasta and
cornmeal was permitted as of December 1996. Industry
was switching to folic acid-containing enrichment
premixes, especially towards the end of 1997, in anticipa-
tion of both US requirements for fortification as of Janu-
ary 1, 1998, and Canadian plans to implement mandatory
fortification. Although this requirement did not come
into force in Canada until late 1998, the Phase I (Novem-
ber 1997 to March 1998) subjects of our study may have
consumed at least some food fortified with folic acid. This
would result in an underestimate of improvements in
blood folate status due to fortification, and might lead us
to miss adverse effects on vitamin B12 status. On the other
hand, the fact that we observed such marked improve-
ments in blood folate status leads us to conclude that
there was a real increase in exposure to folic acid through
fortification, over the study period.
Another limitation of this study is the possible underesti-
mation of folic acid intake due to fortification. Our calcu-
lations were based on the assumption that manufacturers
are fortifying flour at the required level. It has been sug-
gested that allowance for "overages" is resulting in higher
amounts in the affected products [41]. Also, for enriched
pasta, the required level of fortification is from a mini-
mum of 0.20 mg/100 g pasta to a maximum of 0.27 mg/
100 g. In our calculations we assumed the minimum level
of fortification.
We initially selected a random sample of subjects through
random digit dialling, and asked eligible respondents for
voluntary participation in the study. The reasonable level
of response for the dietary questionnaire and blood sam-
pling among rural and urban women aged 19–44 years
suggests that with caution, we can generalize the results to
all Newfoundland women of childbearing age. However,
these findings may not be representative of the rest of
Canada because of population differences in factors such
as genetic background and dietary behaviour. These differ-
ences may also affect the generalizability of the NTD
trend.
The sample response rate for the dietary questionnaire
and blood sampling in seniors was approximately 45%
both in Phase I and in Phase II. Many of the refusals to
participate were due to illness of the eligible person. Fur-
thermore, seniors residing in long term care settings were
not included. Thus our sample population of seniors may
be healthier than the general population age 65 and over
in the province.
Conclusions
The implementation of food fortification with folic acid
has been accompanied by a marked decrease (78%) in the
rate of NTDs in Newfoundland. The blood folate status of
women aged 19–44 years improved following mandatory
fortification. There is no evidence of adverse effects of the
current levels of fortification on individuals aged 65 years
and older. Specifically, there is no evidence to suggest an
adverse effect of folic acid fortification on detection of
abnormalities in vitamin B12 status based on biochemical
and haematological indices.
Based on these findings, mandatory food fortification
with folic acid should continue in Canada at the current
levels. Over the time period of this study, the proportion
of women aged 19–44 years taking a vitamin supplement
containing folic acid increased. It was not possible to
determine the magnitude of the separate contributions of
fortification and supplementation to the decline in NTDs.
Therefore, we recommend that public health efforts to
promote awareness of the importance of folic acid supple-
mentation among women of childbearing age continue.
Ongoing surveillance of NTDs in Newfoundland and
other parts of Canada is necessary to determine if the
decline in NTD rate is maintained, and to enable further
evaluation of prevention strategies. National surveillance
of congenital anomalies including NTDs is a critical
public health function that should be strengthened where
necessary.
We look forward to the results of a current epidemiologic
study, funded by the Canadian Institutes of Health
Research (CIHR), of NTDs in 7 Canadian provinces
between 1993 and 2002. There is also research into the
relationship between increased folic acid consumption
and reduced risk of other congenital anomalies, cardio-
vascular disease and cancer [42-45]. As this body of
knowledge grows, public health practitioners and regula-
tors in Canada and internationally will have more evi-
dence with which to refine existing disease prevention
policies and develop new ones.
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